Talaris Therapeutics, Inc.

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

89157D105

SEDOL

N/A

CIK

0001827506

talaristx.com

LEI:

FIGI: BBG00NX995R3

TALS

Talaris Therapeutics, Inc.

GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology

PROFILER

NAME

Talaris Therapeutics, Inc.

ISIN

US89157D1054

TICKER

TALS

MIC

XNAS

REUTERS

TALS.OQ

BLOOMBERG

TALS US

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Fri, 02.08.2024

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Research & Analysis

Thu, 27.06.2024

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

Research & Analysis

Thu, 23.05.2024

Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024

Research & Analysis

Mon, 13.05.2024

Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Talaris Therapeutics, Inc.

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Newsletter